Skip to main content

The Vectra® test with cardiovascular risk for assessing patients with rheumatoid arthritis

The Vectra® test with cardiovascular (CV) risk incorporates a personalized assessment of inflammation to predict a rheumatoid arthritis (RA) patient’s risk for a CV event in the next three years.


The Vectra® test with CV risk provides an actionable result at point of care that highlights the role of reducing systemic inflammation associated with RA.1-3

50% Patients with RA have approximately 50% greater risk for CV disease compared to the general population.
30% 30% of CV risk in patients with RA is attributed to systemic inflammation and other RA related factors.
Risk factors Traditional CV risk factors do not fully explain the increased CV risk seen in RA patients.

The science of the Vectra® test with CV risk

  • The Vectra® test with CV risk incorporates the patient’s Vectra® score, three blood biomarkers, age, and history of diabetes, hypertension, CV disease, and tobacco use.

  • The Vectra® test with CV risk has been developed and validated utilizing over 30,000 Medicare patients with RA.

  • The Vectra® test with CV risk has been externally validated in a younger independent cohort whose median age was 54.

  • The Vectra® test with CV risk is unique because it incorporates personalized multi-biomarker-based assessment of RA inflammation to predict a patient’s CV risk.

  • The Vectra® test with CV risk accurately predicts CV events in patients with low, moderate, or high Vectra® scores.

The Vectra® test with CV risk and the Vectra® test clinical data

Derivation and internal validation of a multi-biomarker-based CVD risk prediction score for RA patients

Cardiovascular disease (CVD) is the leading cause of mortality for patients with RA, accounting for 30 – 40% of deaths. Patients with RA have approximately 50% greater risk for CVD compared to the general population. Accurate CVD risk prediction could improve care for RA patients. The Vectra® test with CV risk provides rheumatologists with a tool for assessing CVD risk to inform the management of traditional CVD risk factors and RA inflammation.3

External validation of multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients

The Vectra® test with CV risk was validated in a cohort younger than, and independent of, the Medicare cohort originally used for test development.

Performance of the multi-biomarker-based CVD risk prediction score in RA patient groups of clinical interest

The Vectra® test with CV risk score predicts risk for myocardial infarction (MI), stroke, and/or fatal CVD in the next three years for RA patients and has been internally validated. Goodness of fit analyses indicated good accuracy overall, and in subgroups based on total Vectra® score, gender, and statin use.

Biomarker-related risk for myocardial infarction and serious infections in patients with RA

High Vectra® scores are associated with an increased risk of hospitalized infection, myocardial infarction (MI) and coronary heart disease (CHD).

vectra

Download the Provider Guide

Download the brochure to learn more about the Vectra® test and how it can help to improve patient and provider decisions.

Test reports: a personalized precision tool

The Vectra® test measures 12 biomarkers and incorporates age, gender and adiposity in adult patients with RA to provide a single score that is an objective measure of inflammation, which reflects disease activity, predicts risk of radiographic progression and informs medical management decisions designed to prevent irreversible joint damage. The Vectra® test is a validated, advanced blood test performed by a CLIA-certified laboratory

Want to Speak to your Labcorp Representative?

Rheumatology Services Hotline: 800-338-1918

Vectra® Customer Service: 877-743-8639


References

  1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-7.
  2. Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel P, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48-54. 3. Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel P, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48-54. 
  3. Curtis, J.R., Xie, F., Crown, C.S. et al. Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. Arthritis Res Ther 22, 282 (2020) https://doi.org/10.1186/s13075-020-02355-0.